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Laboratory of Bacteriology and Virology, Le Dantec Hospital,a and Laboratory of Parasitology, Faculty of Medicine and Pharmacy, Cheikh Anta Diop University,e Dakar,
Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USAb; Departments of Molecular Microbiology and
Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, USAc; Boston Children’s Hospital, Department of GI/Nutrition,
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Plasmodium falciparum utilizes multiple ligand-receptor interactions for invasion. The invasion ligand EBA-175 is being devel-
oped as a major blood-stage vaccine candidate. EBA-175 mediates parasite invasion of host erythrocytes in a sialic acid-depen-
dent manner through its binding to the erythrocyte receptor glycophorin A. In this study, we addressed the ability of naturally
acquired human antibodies against the EBA-175 RII erythrocyte-binding domain to inhibit parasite invasion of ex vivo isolates,
in relationship to the sialic acid dependence of these parasites. We have determined the presence of antibodies to the EBA-175
RII domain by enzyme-linked immunosorbent assay (ELISA) in individuals from areas of Senegal where malaria is endemic with
high and low transmission. Using affinity-purified human antibodies to the EBA-175 RII domain from pooled patient plasma,
we have measured the invasion pathway as well as the invasion inhibition of clinical isolates from Senegalese patients in ex vivo
assays. Our results suggest that naturally acquired anti-EBA-175 RII antibodies significantly inhibit invasion of Senegalese para-
sites and that these responses can be significantly enhanced through limiting other ligand-receptor interactions. However, the
extent of this functional inhibition by EBA-175 antibodies is not associated with the sialic acid dependence of the parasite strain,
suggesting that erythrocyte invasion pathway usage by parasite strains is not driven by antibodies targeting the EBA-175/glyco-
phorin A interaction. This work has implications for vaccine design based on the RII domain of EBA-175 in the context of alter-
native invasion pathways.
Erythrocyte (RBC) invasion is an essential step of the Plasmo-dium falciparum life cycle involving multiple specific interac-
tions between parasite ligands and erythrocyte receptors, termed
invasion pathways.Plasmodium falciparumuses different invasion
pathways to invade human erythrocytes, relying on two primary
families of invasion ligands: the erythrocyte binding antigen
(EBA) family and the reticulocyte binding protein homolog
(PfRH) family (1–3).
EBA-175 is located in the apicalmicronemes ofmerozoites and
mediates parasite invasion of host erythrocytes in a sialic acid-
dependent manner (4, 5) EBA-175 is divided into several regions,
annotated I toVII; region II of the protein (RII) has a cysteine-rich
motif that is also present in the Duffy-binding proteins of Plasmo-
dium vivax and Plasmodium knowlesi (6, 7). EBA-175 RII has two
subdomains, F1 and F2. The F2 domain has been shown biochem-
ically to bind to red blood cells (8, 9); this binding is dependent on
sialic acid on glycophorin A (Gly A) (4, 5). The crystal structure of
EBA-175 RII has confirmed both the requirement for sialic acid
and the necessary dimerization of glycophorin A (10). In addition
to the RII binding domain, there is a large dimorphic domain in
region III known as the F/C segment (containing the F and C
segments [F-seg and C-seg]). The RII and the dimorphic F-seg,
and C-seg domains of EBA-175 have been shown to be under
diversifying selection by the human immune response in global
populations (11–13). Previous studies have shown that antibodies
recognize all of these domains (14), although the functional im-
pact of these human antibodies on invasion is unknown.
The EBA-175/glycophin A pathway is one of the dominant
invasion pathways used by P. falciparum parasites to invade the
red blood cells in a sialic acid-dependent fashion (4, 5). Genetic
disruption of EBA-175 results in a change in invasion pathway for
sialic acid-dependent parasite strains (15).
Several studies have shown that a humoral response against
EBA-175 is generated in subjects living in areas of endemicity (13,
14, 16–22). Some studies have reported that antibodies against
EBA-175 domains correlate with protection from symptomatic
malaria but not reinfection (22), and others show marginal, but
not significant, protection (14). While antibodies induced in ex-
perimental animals against EBA-175 RII have invasion-inhibitory
activity in vitro (17, 23, 24), few studies have measured EBA-175-
based protection against clinical malaria in humans.
TheRII binding domain of EBA-175 is currently being pursued
as a vaccine candidate antigen (25, 26) because of its high level of
sequence conservation, its expression among laboratory and pa-
tient parasite isolates (8, 27), and the observation that there is an
age-dependent acquisition of antibodies in endemic populations
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(14, 20). In animal studies, the EBA-175 RII vaccine was shown to
be safe and immunogenic, producing antibodies that inhibit inva-
sion, with protection of 1 of 3 vaccinated Aotus monkeys from
disease (26). It has been observed that antibodies raised against
EBA-175 RII in rabbits inhibit invasion regardless of the invasion
pathway utilized (23). Prior experiments show that total IgG ac-
quired by malaria-exposed individuals has the ability to inhibit
erythrocyte invasion in an invasion pathway-dependent manner
(19). In this study, we demonstrated that antibodies against EBA-
175 RII from naturally exposed humans can inhibit invasion by P.
falciparum clinical isolates and analyzed the dependence of inhi-
bition on the invasion pathway.
MATERIALS AND METHODS
Study sites and samples. Approval for this study was granted by the In-
stitutional Review Board of the Harvard School of Public Health and by
the Ethics Committee of the Ministry of Health in Senegal. Whole blood
was collected in EDTA Vacutainers (for separation of plasma) from Sen-
egalese consenting patients with uncomplicatedmalaria during the trans-
mission season (September to December 2004 and 2005 in Velingara and
in the years 2009 to 2011 in Thies). Individual patient plasma samples
were collected fromThies (n 133), an area of low endemicity in Senegal
located 70 km from Dakar (entomological inoculation rate [EIR] 1 to
10), and Velingara (n 94), a region of hyperendemicity situated in the
southeast, 570 km from Dakar (EIR 100). In Thies, the median patient
age is 21 years, whereas in Velingara, the median patient age is 7 years. In
Velingara, 38% of the patients were female and 62% of the patients were
male, whereas in Thies, 34% of the patients were female and 66% of the
patients were male. Plasma from 75 unexposed individuals living in an
area of nonendemicity (Boston, MA) were collected as negative controls.
Plasmodium falciparum patient isolates. Five milliliters of parasit-
ized bloodwas collected in EDTAVacutainers frompatients with uncom-
plicated malaria from Thies during the transmission seasons (October to
November) from 2009 to 2011. Patients with a parasitemia level of0.7%
were included in invasion and inhibition experiments. The diagnosis of
malaria was done by thick smear and rapid diagnosis test (RDT), and
parasitemia was assessed by thin smear counted using a Miller reticle.
Parasitized cells were washed 3 times with unsupplemented RPMI me-
dium prior to assay plating.
Recombinant EBA-175 RII protein. Recombinant RII was produced
by oxidative refolding optimized for Duffy-binding-like (DBL) domains
as has been described for other DBL domain proteins (28–32). Briefly,
amino acids 145 to 761 (RII) from EBA-175 strain 3D7 were expressed in
E. coli BL21 cells using a pET-28 vector. Denatured protein was extracted
from inclusion bodies using 6 M guanidine hydrochloride, 50 mM Tris
(pH 8), 100 mM NaCl, and 5 mM dithiothreitol (DTT) and refolded via
rapid dilution in 400mML-arginine, 50mMTris (pH 8.0), 10mMEDTA,
0.1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM reduced glutathi-
one, and 2 mM oxidized glutathione. The refolded RII was concentrated
using Amicon concentrators and then purified by ion-exchange chroma-
tography using a Mono S column followed by gel filtration chromatogra-
phy using a Superdex 200 16/60 column.
ELISA. Individual patient plasma and pooled Velingara plasma and
affinity purification fractions were tested for the presence of antibodies
against EBA-175 RII by enzyme-linked immunosorbent assay (ELISA).
The recombinant proteins were coated in 96-well plates (Dynex Technol-
ogies; Immulon 1B) in phosphate-buffered saline (PBS) and incubated
overnight at 4°C. The plates werewashed three timeswith PBS plus Tween
20 (PBST), then blocked with 1% milk in PBST, and incubated at room
temperature for 2 h. Plates were washed 3 times with PBST, individual
Senegalese sample plasma was added to the plates in duplicate (1/800),
and plates were again incubated at room temperature for 2 h. Plates were
washed 3 times with PBST before a 1/8,000 dilution of horseradish per-
oxidase (HRP)-conjugated goat anti-human IgG secondary antibody
(Southern Biotech) was added, and plates were incubated at room tem-
perature for 2 h. Plates were washed 5 times with PBST, and 100 l of
Sureblue TMB substrate (KPL) was added to each well and allowed to
develop for 10 min; the reaction were stopped by adding an equal volume
of 1 N filtered HCl in the same room as the plate reader to avoid delay
causing precipitation. The optical densities (ODs) were read at 450 nmon
an ELISA plate reader. Positive cutoffs for the RII recombinant protein
were determined as an OD of 3 times the standard deviation of the mean
for 72 plasma samples from unexposed individuals from Boston.
Affinity-purified antibodies from pooled patient plasma. A total of
200 pooled patient plasma from an area of high endemicity (Velingara)
were used to affinity purify the antibodies to RII protein coupled to CNBr
Sepharose (Sigma). Column chromatography was performed on an
AktaFPLC (GE Healthcare) using standard techniques. Briefly, pooled
plasma was diluted 1:10 with PBS and loaded onto the affinity column at
1 ml/min. The column was washed with PBS until a stable A280 baseline
was reached. Antibodies were eluted with 100 mM glycine (pH 2.5) in
500-l fractions inwells containing 50l of 1MTrisHCl (pH8.0) to limit
the amount of time the antibodies were exposed to low pH. Fractions
containing the peaks were pooled, dialyzed into 1 PBS, and concen-
trated. Antibodies to EBA-175 recombinant RII protein were tested for
enrichment and specificity by ELISA.
Invasion assay.The invasion assay was carried as previously described
(15). Infected erythrocytes were incubatedwith enzyme-treated RBCs in a
final volume of 50 l at 2% hematocrit for approximately 48 h (or until
reinvasion as assessed bymicroscopy). The erythrocytes were treated with
the following: neuraminidase (66.7 mU/ml; Roche), trypsin (1.0 mg/ml;
Sigma), chymotrypsin (1.0 mg/ml; Worthington), low trypsin (66.7 g/
ml)-chymotrypsin, neuraminidase-trypsin-chymotrypsin (NTC; nega-
tive control), and RPMI medium only (positive control). Upon reinva-
sion, assays were analyzed by both microscopy and staining with SYBR
green I (Invitrogen), as previously described (33). Flow data were ana-
lyzed using FlowJo 8.8.6 (Tree Star). Inclusion criteria for further analysis
include a parasite multiplication rate (PMR) of1 and invasion in posi-
tive-control samples (RPMImedium)2-fold higher than in the negative
control (NTC). Invasion for each enzyme treatment is displayed as a per-
centage of invasion of RPMI medium-treated cells.
Invasion inhibition assay. Affinity-purified antibodies were incu-
batedwith clinical isolates at a final concentration of 10 to 50g/ml in one
round of invasion inhibition assays, and invasion was measured by flow
cytometry. The starting parasitemia was 0.7% to 1%. Untreated red blood
cells or chymotrypsin-treated red blood cells at 4% hematocrit were incu-
bated with infected erythrocytes to obtain a parasitemia of 0.3 to 0.5% in
25 l per well, in duplicate. Parasites were incubated for 48 h (or until
reinvasion as assessed by microscopic examination of each assay). Inva-
sion (or inhibition) is displayed as percentage of invasion (or inhibition)
of Boston unexposed plasma.
Statistical analysis. Comparison of EBA-175 RII titers by age group
and RII inhibition stratified by invasion pathway were assessed using a
Mann-Whitney U test. Comparisons between EBA-175 RII positivity by
ELISA and age group were assessed using the Fisher exact test. Compari-
sons between inhibition intoRPMImedium-treated cells and chymotryp-
sin-treated cells were conducted using the Mann-Whitney U test. Com-
parison of inhibition of invasion into RPMI medium-treated cells versus
receptor-restricted erythrocytes was conducted using aWilcoxon ranked-
pair test. Statistical analyses were performed using GraphPad Prism 5
software.
RESULTS
Immune recognition of EBA-175 domains in different regions
of endemicity in Senegal.We determined the immune reactivity
to different domains of EBA-175 by measuring levels in plasma of
IgG to region II (RII) (Fig. 1A). Total IgG reactivity was deter-
mined for 133 plasma samples from Thies and 94 from Velingara
and was found to be 35% positive in both sites overall. As the
Invasion Pathway Does Not Inﬂuence EBA-175 Inhibition
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endemicities at these sites are dramatically different, we assessed
the age-dependent acquisition of anti-RII antibodies in a site-de-
pendent manner (Fig. 1B and D). When associating EBA-175 RII
positivity with age group, positivity was not significantly corre-
lated with age in Thies (Fisher exact test, P  0.133), whereas
positivity was associated with increased age in Velingara (Fisher
exact test, P  0.0001) (Fig. 1B). Similarly, titers of antibody to
EBA-175 RII did not increase significantly with age in Thies
(Mann-Whitney U test, P 0.0894), whereas an increase in titer
with age was significant in Velingara (Mann-Whitney U test, P
0.0001) (Fig. 1D).We further compared the two areas of endemic-
ity using the same age group for both sites. Because of the low
number of young children among the patients from Thies, we
used the intermediate cutoff of 15 years of age; we observed similar
trends. When associating EBA-175 RII positivity with age group,
positivity was not significantly correlated with age in Thies (Fisher
exact test, P  0.3547), whereas positivity was associated with
increased age inVelingara (Fisher exact test,P 0.0007) (Fig. 1C).
Similarly, titers of antibody to EBA-175 RII marginally increased
with age in Thies (Mann-Whitney U test, P 0.0305), whereas a
significant increase in titer with age was observed in Velingara
(Mann-Whitney U test, P  0.0002) (Fig. 1E). Together, these
data demonstrate the presence of antibodies to EBA-175 domains
in the Senegalese population that are acquired in an age-depen-
dent manner.
Inhibition of invasion for lab and field isolates with RII anti-
bodies. We next addressed the functional activity of these anti-
bodies in inhibiting P. falciparum invasion. We affinity purified
immunoglobulin against the RII domain from 200 pooled plasma
samples fromVelingara, a region of hyperendemicity, that showed
increased RII reactivity by ELISA (Fig. 2A). These affinity-purified
antibodies show 1,000-fold enrichment of RII-specific IgG rela-
FIG1 IgG response to EBA-175RII increaseswith age in Senegal. (A) Schematic of EBA-175 illustrating theRII domain of interest. TM, transmembrane domain;
F-seg, F segment; C-seg, C segment. (B) IgG responses measured by ELISA in Thies (n 133), where the median age in the study population was 21 years, and
Velingara (n  94), where the median age in the study population was 7 years. Positive RII responses are not correlated with age in Thies but are positively
correlated with age in Velingara. ns, not significant. (C) IgG responses measured by ELISA in Thies and Velingara, stratified by the intermediate age group of 15
years. Positive RII responses are not correlated with age in Thies but are positively correlated with age in Velingara. P values for the Fisher exact test associating
ELISA positivity with age are shown in panels B and C. (D) IgG levels (OD) were measured by ELISA in Thies and Velingara and stratified by region-specific age
group (21 years in Thies and 7 years in Velingara). ELISA OD significantly increased with age in Velingara but not in Thies (D). (E) IgG levels (OD) measured
by ELISA inThies andVelingara, stratified by the intermediate age group of 15 years. Positive RII responses are correlatedwith age in both Thies and inVelingara.
P values displayed were derived from Mann-Whitney U tests for panels D and E. Median ELISA titers are shown.
Badiane et al.
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tive to the Velingara pool as measured by ELISA (Fig. 2A).
We used these affinity-purified antibodies to test invasion inhi-
bition of laboratory isolates that utilize alternative invasion
pathways (3D7, sialic acid independent; W2mef, sialic acid
dependent). We tested the specificity of inhibition using EBA-
175 knockout parasite lines as controls (3D7175 and
W2mef175). To more closely investigate the role of EBA-175,
we also performed invasion assays using red blood cells treated
with chymotrypsin, which cleaves many receptors but does not
cleave the EBA-175 receptor, glycophorin A.We observedmin-
imal inhibition of invasion into RPMI medium-treated red
blood cells for wild-type 3D7 and EBA-175 knockout lines
(Fig. 2B). Treatment with chymotrypsin revealed significant
inhibition of wild-type 3D7 but not the EBA-175 knockout
(Fig. 2C), demonstrating the specificity of the affinity-purified
RII antibodies. We performed these experiments with recep-
tor-restricted cells at the physiological concentrations of 10
g/ml and 50 g/ml of RII antibody (Fig. 2D and E). At these
concentrations, W2mef and 3D7 were equally inhibited, de-
spite alternative invasion pathway utilization, as has been ob-
served by others (23), and inhibition increased with antibody
concentration (Fig. 2D and E). These data show inhibition spe-
cific to RII but not necessarily dependent on invasion pathway
utilization in laboratory isolates. We tested the inhibitory re-
FIG 2 Receptor restriction increases inhibition of EBA-175-expressing parasites by human anti-RII antibodies. (A) Fold enrichment of affinity-purified human
antibodies to EBA-175 RII. RII-A and RII-B are two different purifications of the same pool from Velingara patients (Vel Pool). BOS pool represents 75
unexposed plasma samples from Boston, pooled. RII void represents the flowthrough (IgG depleted of RII antibodies by affinity purification). At 10 g/ml,
inhibition levels of 3D7 and 3D7 EBA-175 knockout parasites were equivalent whenmeasured in RPMImedium-treated cells (B); however, a significant increase
in inhibition was observed when receptors were restricted by chymotrypsin (C). Inhibition of 3D7 and W2mef parasites (but not EBA-175 knockouts) was
observed in chymotrypsin-treated (receptor-restricted) erythrocytes at the physiological concentrations of 10g/ml (D) and 50g/ml (E). Error bars correspond
to median invasion and interquartile range.
Invasion Pathway Does Not Inﬂuence EBA-175 Inhibition
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sponse to affinity-purified RII antibodies in a larger number of
clinical isolates using the validated concentration of 10 g/ml.
Association between invasion pathway utilization and RII
inhibition. To determine the role of the invasion pathway in in-
hibition with RII antibodies, we expanded our analyses to study
inhibition in a large number (n 66) of ex vivo Senegalese parasite
isolates spanning three transmission seasons (2009 to 2011). Dur-
ing the 3 years of collection, 66 patient samples met our inclusion
criteria (see Materials andMethods): 27 samples in 2009, 22 sam-
ples in 2010, and 17 samples in 2011.
Invasion inhibition assays were performed with RPMI medium-
treated red blood cells and chymotrypsin-treated cells at a 10-
g/ml concentration of affinity purified anti-RII antibodies. We
observed variation in inhibition of the pooledVelingara immuno-
globulin; however, this inhibition did not significantly increase
when erythrocytes were treated with chymotrypsin (Wilcoxon
matched-pair test, P 0.3815) (Fig. 3A). In contrast, while inhi-
bition with affinity-purified RII antibodies was observed with
both RPMI medium- and chymotrypsin-treated cells, signifi-
cantly higher inhibition was observed with chymotrypsin-treated
cells (Wilcoxon matched-pair test, P 0.0025) (Fig. 3B). We ad-
dressedwhether this variation could be due to alternative invasion
pathway utilization by measuring relative utilization of invasion
pathway by enzymatic treatment and associating the levels of in-
vasion with the levels of anti-RII inhibition (Fig. 4).
We observed variation in invasion pathways for ex vivo P. fal-
ciparum isolates from Thies, as we have previously reported (34,
35) (Fig. 4A). Interestingly, we saw no significant differences in
invasion pathway utilization year to year (Kruskal-Wallis: neur-
aminidase, P 0.5837; chymotrypsin, P 0.3205), implying that
invasion pathways in a given region may be stable over time (Fig.
4B). Based on the invasion pathway data, 61% (n  40) of the
strains were sialic acid dependent as defined by invasion of less
than 50% into neuraminidase-treated erythrocytes, measured by
microscopy. When we compared RII inhibition of sialic acid-de-
pendent versus independent strains (using the 50% cutoff), we
observed no difference in the median level of RII inhibition
(Mann-Whitney U test, P  0.3338) (Fig. 4C). Similarly, we ob-
served no difference in the median level of RII inhibition of chy-
motrypsin-sensitive versus chymotrypsin-resistant strains (using
the 50% cutoff) (Mann-WhitneyU test, P 0.6677) (Fig. 4D). To
determine whether there is a difference in dependent versus inde-
pendent isolates, we divided the data into quartiles and as-
sessed the 25th percentile (dependent) and the 75th percentile
(independent) for their levels of RII inhibition. With both
RPMI medium- and chymotrypsin-treated cells, we observed
no significant difference in the level of RII inhibition (as deter-
mined by the Mann-Whitney U test) (data not shown).
Association between antibody reactivity and RII inhibition.
We assessed individual patient RII titers correlation with either
invasion pathway utilization or RII inhibition by measuring RII
reactivity by ELISA (Fig. 1D and E) and comparing ELISA OD
with percent invasion and percent RII inhibition for patients from
Thies for which we had both invasion and inhibition data. There
was no significant association by Spearman rank test for either RII
titer and invasion pathway (neuraminidase or chymotrpysin) or
RII titer and RII inhibition (data not shown).
DISCUSSION
In this study, we found that antibodies against EBA-175 are ac-
quired in areas of both low endemicity and hyperendemicity and
that IgG antibodies to EBA-175 RII are acquired in an age-depen-
dent manner. In Thies, the majority of the patients are adults with
a median age of 21 years, while in Velingara, the median age is 7
years. In Velingara, the antibody acquisition occurs at an earlier
age and is more dramatic than in Thies, which is what would be
expected given the intensity of exposure (Veligara EIR  100;
Thies EIR 10).
Despite the difference in endemicities, the level of EBA-175
ELISA positivity observed in Senegal (35%) is different fromwhat
has been reported by others (14, 20). In fact, in a study done in an
area of holoendemicity in Kenya, the antibody positivity against
the RII domain was high 98.7% (20), whereas in Gambian chil-
dren and Nigerian adults, the positivities were found to be 43%
and 70%, respectively (14). Our results show much lower anti-
body prevalence for RII in both sites (35%), despite the difference
in endemicities. Our results could be explained by the decreasing
malaria pressure in Senegal or differences in study populations, as
our patients had uncomplicated malaria at the time plasma anti-
bodies were isolated. Occasionally, differences in apparent anti-
FIG 3 Receptor restriction increases inhibition of ex vivo Senegalese isolates by human anti-RII antibodies but not total IgG. While limiting the receptor
repertoire by treatment with chymotrypsin does not affect the inhibition of total Velingara immunoglobulin (A), it does increase the inhibition with anti-RII
human affinity-purified antibodies (B). Wilcoxon ranked-pair tests were performed with a significance level of 0.05. Error bars correspond to median invasion
and interquartile range.
Badiane et al.
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body reactivity are due to the quality of protein used for ELISA;
misfolded bacterially expressed protein can display epitopes that
are not physiologically relevant, resulting in spuriously high
ELISA positivity. We note that the RII protein we used was vali-
dated for correct folding andwas the same as that used to solve the
crystal structure of EBA-175 RII (28, 29).
Since vaccines should be designed to protect exposed individ-
uals from diverse field strains, it is imperative to assess the inva-
sion efficiency of field isolates in the presence of anti-RII EBA-175
antibodies. While a few studies have been performed using affin-
ity-purified human antibodies to assess merozoite inhibition, our
study has performed this analysis using affinity-purified human
antibodies to EBA-175 RII using ex vivo parasite isolates from
patients. In this study, we tested the strains with two concentra-
tions of affinity-purified human anti-RII antibodies: 10 and 50
g/ml, which are in the range of the physiological concentrations
10 to 100 g/ml (36). Others have used affinity-purified human
antibodies to other invasion ligands at similar concentrations and
have observed various degrees of inhibition. We show for the first
time increased inhibition of the field isolates in receptor-restricted
erythrocytes. This finding supports the hypothesis that interrupt-
ing the EBA-175/glycophorin A interaction in conjunction with
other invasion pathways could be a viable strategy to significantly
inhibit blood-stage proliferation (23, 24, 37, 38).
Others have also observed a lack of correlation between inva-
sion pathway and inhibition in studies using higher concentra-
tions of antibodies and laboratory lines (23, 24, 39). We found
similar levels of inhibition of the laboratory strains 3D7 and
W2mef with anti-RII antibodies when invasion into receptor-re-
stricted chymotrypsin-treated erythrocytes was measured,
whereas both EBA-175 knockouts are not inhibited by anti-RII
antibodies. While this is an important observation with diverse
laboratory isolates, we sought to determine whether this observa-
tionwas true in the context of naturally acquired antibodies and ex
vivo parasites from clinical malaria cases invading via naturally
divergent invasion pathways.
We found that the invasion pathways utilized by the Senegalese
population of parasites were stable over the 3 years of our study.
Further, similar to the observations with laboratory isolates and
knockouts, the sialic acid dependence of the field isolates, associ-
ated with the EBA-175/GPA pathway, did not correlate with func-
tional inhibition by anti-RII antibodies. This is most likely due to
the sialic acid-dependent pathway being a complex phenotype
resulting from the contribution of multiple ligand-receptor inter-
actions, challenging the prevailing dogma that the EBA-175/GPA
pairing is at the top of the ligand-receptor hierarchy (40). While
the EBA-175/GPA pathway is an important invasion pathway in
Senegal (61% of the strains being sialic acid dependent), it is
clearly not the only pathway being used by parasites. The ability to
inhibit invasion with the pre-affinity-purified Velingara pool im-
FIG 4 Variation in inhibition is not linked to ex vivo invasion pathways. (A) Invasion pathway was measured for 66 ex vivo P. falciparum isolates from Thies,
Senegal, from 2009 to 2011. (B) Invasion pathways remain stable over time (Kruskal-Wallis; PNS). Antibody inhibition (anti-RII antibodies) into chymotrpy-
sin (Chy)-treated cells was compared for parasites invading via either neuraminidase (Nm)-sensitive and -resistant pathways (C) or chymotrypsin-sensitive and
-resistant pathways (D). Cutoffs shown represent themedian inhibition into both neuraminidase-treated (C) and chymotrypsin-treated (D) cells; however, data
were analyzed using the cutoff of 50% as well, and no significant differences were observed (Mann-Whitney U test, P  0.05 [data not shown]). Error bars
represent median and interquartile range.
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plies that other non-RII antibodies also play an important role in
invasion inhibition, and ideally, a vaccine targetingmultiple inva-
sion pathways would be designed and employed, as targeting a
dominant pathway alone will be insufficient for protection.
There is a critical need for an effective and strain-transcendent
malaria vaccine. RTS,S is the most advanced malaria vaccine to
date; it targets the sporozoite stage and is in phase III clinical trials.
In a recent study conducted with children, the vaccine showed an
efficacy of 30% in an intention-to-treat analysis (41). While such
results are promising, they are far from the goal of sterile protec-
tive immunity. In the face of such a challenge, there has been a
recent renewed interest in developing blood-stage vaccines for
malaria, specifically strain-transcending vaccines based on a com-
bination of blood-stage antigens (24, 38, 42). Although a recom-
binant EBA-175 vaccine is currently in phase I clinical trials (43),
few other blood-stage vaccine candidates have progressed beyond
phase I clinical trials, largely due to low levels of protection and
allele-specific immunity (42, 44–48).
Here, we show that naturally acquired human antibodies
against EBA-175 RII can inhibit invasion of clinical isolates of P.
falciparum parasites to various degrees; however, this inhibition is
not complete. While we conclude that invasion pathway differ-
ences are not the primary reason for differential inhibition, it will
be important to determine whether variation in expression or se-
quence of RII in these clinical isolates or other factors can influ-
ence the functional activity of anti-RII antibodies. To our knowl-
edge, this is the first report of invasion-inhibitory activity of
naturally acquired antibodies to EBA-175 using ex vivo P. falcipa-
rum parasite isolates. Our data suggest that the RII region of EBA-
175 elicits invasion-inhibitory antibodies in humans and that this
region may be an effective antigen as a component of a multisub-
unit blood-stage vaccine (19, 23, 24, 38).
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